# GLMD — Galmed Pharmaceuticals Ltd · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GLMD  
**Sources:** 12  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-glmd-galmed-pharmaceuticals-ltd-catalysts-narrative-risk-10512

---

# Galmed Pharmaceuticals Ltd. (ticker: GLMD → EOCN) — Research Note

**Important context on identity:** As of the current date (2026-11-01), Galmed Pharmaceuticals is trading under the new name **Eocene Ltd.** and ticker **EOCN**, after announcing the rebranding on September 9, 2026 [[1]](https://www.rttnews.com/companies/41322/galmed-pharmaceuticals-ltd-glmd), [[4]](https://squawknews.com/ticker/GLMD), [[10]](https://www.prnewswire.com/news/galmed-pharmaceuticals-ltd./). The legacy ticker GLMD is effectively retired: Yahoo Finance's symbol lookup returns no results for "GLMD" [[9]](https://finance.yahoo.com/quote/GLMD/latest-news/), and SEC filing trackers now list the issuer as EOCN [[11]](https://www.marketbeat.com/stocks/NASDAQ/EOCN/sec-filings/). I treat GLMD and EOCN as the same security for the remainder of this note.

---

## 1. Recent Catalysts (roughly August–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-glmd-galmed-pharmaceuticals-ltd-catalysts-narrative-risk-10512 (free to sign up)._